Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Gastrointestinal 1Endocrine 1

Conditions

Carcinoma, Non-Small-Cell Lung 55Breast Neoplasms 38Prostatic Neoplasms 29Lung Neoplasms 28Multiple Myeloma 22Neoplasms 19Ovarian Neoplasms 17Colorectal Neoplasms 17Leukemia, Lymphocytic, Chronic, B-Cell 16Neoplasm Metastasis 15Parkinson Disease 4, Autosomal Dominant Lewy Body 14Carcinoma, Renal Cell 13Endometrial Neoplasms 12Small Cell Lung Carcinoma 11Pancreatic Neoplasms 11Urinary Bladder Neoplasms 10Stomach Neoplasms 10Squamous Cell Carcinoma of Head and Neck 9Lymphoma, Follicular 9Fallopian Tube Neoplasms 9Non-Muscle Invasive Bladder Neoplasms 8Myasthenia Gravis 8Leukemia, Myeloid, Acute 8Colonic Neoplasms 8Burkitt Lymphoma 7Recurrence 6Esophageal Neoplasms 6Adenocarcinoma 6Triple Negative Breast Neoplasms 5Melanoma 5

Interventions

Lutetium-177 1Lutetium 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Advanced Gastroenteropancreatic Neuroendocrine Tumor × 30 days × Clear all
NCT05884255 2026-05-19

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Recruiting
220 enrolled
EndocrineGastrointestinalNET

Advanced Gastroenteropancreatic Neuroendocrine Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡